0001399529-21-000025.txt : 20210127
0001399529-21-000025.hdr.sgml : 20210127
20210127184108
ACCESSION NUMBER: 0001399529-21-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210125
FILED AS OF DATE: 20210127
DATE AS OF CHANGE: 20210127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brown Bob D
CENTRAL INDEX KEY: 0001598479
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36281
FILM NUMBER: 21561370
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGEPARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER NAME:
FORMER CONFORMED NAME: Brown Bob
DATE OF NAME CHANGE: 20140129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001399529
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205993609
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617 621 8097
MAIL ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
wf-form4_161179085557445.xml
FORM 4
X0306
4
2021-01-25
0
0001399529
Dicerna Pharmaceuticals Inc
DRNA
0001598479
Brown Bob D
C/O DICERNA PHARMACEUTICALS, INC.
75 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Scientific Ofr., EVP R&D
Common Stock
2021-01-25
4
M
0
16630
9.09
A
43147
D
Common Stock
2021-01-25
4
S
0
21630
25
D
21517
D
Employee Stock Option (Right to Buy)
9.09
2021-01-25
4
M
0
16630
0
D
2026-01-08
Common Stock
16630.0
108370
D
The Reporting Person sold an aggregate of 21,630 shares of Common Stock on January 25, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 2.15% of 1,006,767 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2020.
As of the transaction date, the option was fully vested. The option vested in 48 monthly installments over the four-year period with a vesting start date of January 8, 2016, subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date.
/s/ Douglas W. Pagan, attorney-in-fact
2021-01-27